Resources & Guides

Complete GLP-3 retatrutide dosage chart showing the Phase 2/3 clinical trial titration from 2mg to 12mg weekly. Includes what to expect at each dose, weight loss results by tier, side effects data, printable download, and free dosing calculator.

Retatrutide activates three hormone receptors at once. Here is what it actually does inside the body: appetite suppression, metabolic shifts, blood sugar regulation, and fat loss, all grounded in published Phase 2 data.

Retatrutide achieved 24.2% weight loss vs semaglutide's 14.9% in trials. Compare triple-agonist vs single-agonist mechanisms, approval status, clinical data, side effects, and find out which GLP-1 medication is right for you.

How much weight can you lose on retatrutide? This guide covers Phase 3 and Phase 2 clinical data, a month-by-month timeline, cross-drug comparison to tirzepatide and semaglutide, body composition breakdown, and what individual factors affect your results.

People search "GLP-3 retatrutide" after hearing the nickname online. There is no GLP-3 receptor. Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon. Here is where the name came from and what it means.

Retatrutide side effects guide: nausea, diarrhea, and other GI symptoms from Phase 2 clinical trial data, plus management strategies.

A practical retatrutide nausea management guide covering the mechanism, Phase 2 trial data, the dose step-back protocol, and dietary strategies.

A side-by-side look at the single, dual, and triple agonists. Trial weight loss runs 14.9% (semaglutide), 20.9% (tirzepatide), and 24.2% (retatrutide), but the trials differ and only one pairing has a head-to-head study.

An educational, pharmacokinetics-grounded explainer of what a tirzepatide to retatrutide transition involves: washout timing, the 2mg restart, GI reset, and the investigational reality.

Retatrutide achieved 24.2% weight loss vs tirzepatide's 20.9%. Compare mechanisms, trial results, side effects, and find out which medication might work better for you.

Retatrutide results from clinical trials show 24.2% weight loss at 48 weeks with the 12mg dose. Detailed breakdown of trial data, timeline of results, body composition changes, and realistic expectations.

Retatrutide is an investigational triple-agonist medication that activates GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24.2% weight loss, the highest ever recorded for a GLP-1 class drug. Learn everything about this breakthrough medication.

A dose-by-dose breakdown of retatrutide phase 3 weight loss results from the TRIUMPH program: TRIUMPH-1 (28.3% at 80 weeks), the 104-week extension (30.3%), TRIUMPH-4 (28.7%), safety data, and what investigational status means for access.

Retatrutide does not prevent lean mass loss, but the proportion lost is similar to other obesity treatments. Here is what the DEXA data shows, why the glucagon receptor is only a hypothesis, and what actually protects muscle.

The TRIUMPH-1 secondary dataset presented at ADA 2026 goes beyond weight loss. Triglycerides fell 41.0%, non-HDL cholesterol 24.2%, systolic blood pressure 12.3 mmHg, and nested substudies showed up to 73.1% less knee pain and up to 60.6% less sleep apnea on retatrutide 12mg.

Retatrutide is not commercially available. Phase 3 results have been reported and Lilly plans a BLA filing in Q1 2027, with approval possible in 2027-2028. In the US, lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). Compounding pharmacies cannot lawfully supply it. Here is everything you need to know about retatrutide availability worldwide.

Retatrutide has no official price. It's still in Phase 3 clinical trials. This guide covers what people actually pay today for research peptides, why compounded retatrutide is not a lawful option, what it will likely cost at commercial launch, and how it compares to tirzepatide and semaglutide.

Retatrutide isn't FDA-approved yet. Lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). This guide covers how to join a trial, who qualifies for expanded access, why compounding pharmacies cannot lawfully supply retatrutide, and what research peptide vendors actually sell, plus what you need to know about safety, legality, and costs.

Retatrutide is the first triple agonist that activates GIP, GLP-1, and glucagon receptors at once. How each receptor contributes to weight loss, why it outperforms single and dual agonists, and what the clinical data shows.